Physician profile
Sanket Patel
NPI 1306296686
$134,349.77
in general payments reported to CMS, 2019-2025
19 companies · $95K in 2025
The $95K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.82 · 2022: $364 · 2023: $279 · 2024: $39K · 2025: $95K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $109K · Travel and Lodging: $11K · Consulting Fee: $7,150 · Food and Beverage: $5,554 · Honoraria: $1,206 · Education: $16.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $108,970.50 |
| Travel and Lodging | $11,057.75 |
| Consulting Fee | $7,150.00 |
| Food and Beverage | $5,554.48 |
| Honoraria | $1,206.00 |
| Education | $16.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $40,590.98 | 2024-2025 | Omvoh |
| Janssen Biotech, INC. | $33,097.36 | 2024-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $31,799.80 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20,206.46 | 2022-2025 | Entyvio, Eohilia |
| E.R. Squibb & Sons, L.L.C. | $4,700.99 | 2024 | Zeposia |
| Genentech, INC. | $1,448.90 | 2025 | |
| Celltrion USA INC. | $1,295.46 | 2024-2025 | Zymfentra, Vegzelma |
| Pfizer INC. | $405.76 | 2023-2025 | |
| Celgene Corporation | $221.71 | 2023-2024 | Zeposia |
| Medtronic, INC. | $157.52 | 2022 | |
| Gilead Sciences, INC. | $95.51 | 2022 | |
| Boston Scientific Corporation | $88.15 | 2021-2023 | |
| Organon LLC | $74.94 | 2024-2025 | Hadlima |
| Glaxosmithkline, LLC. | $56.15 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.65 | 2024-2025 | Xifaxan |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $34.27 | 2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $18.80 | 2024 | Dupixent |
| Ge Healthcare | $16.82 | 2025 | |
| Janssen Scientific Affairs, LLC | $4.54 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanket Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.